Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high‐risk subgroups
Antonio Cuneo(Arcispedale Sant'Anna), Gian Matteo Rigolin, Olga Sofritti(University of Ferrara), Giulia Daghia(University of Ferrara), Maria Ciccone(Arcispedale Sant'Anna), Elena Saccenti(University of Ferrara), Massimo Negrini(University of Ferrara), Francesco Cavazzini(Arcispedale Sant'Anna)
Cited by 22
Related Papers
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Isolation and characterization of CD146+ multipotent mesenchymal stromal cells
|Experimental Hematology|2008|254
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
|Blood|2015|215
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
|Blood|2019|215
Oncogenic Role of <i>miR-483-3p</i> at the <i>IGF2/483</i> Locus
|Cancer Research|2010|213